{"title":"常规治疗失败后，Nivolumab 免疫疗法再挑战治疗进展期喉鳞癌：CARE病例报告","authors":"","doi":"10.1016/j.anorl.2024.02.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Analysis of rechallenge with nivolumab<span> as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma<span> following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.</span></span></p></div><div><h3>Observation</h3><p><span><span>A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with </span>chemoradiotherapy<span> and surgery, was initially treated for recurrence with carboplatin<span>, 5-fluorouracile (FU) and cetuximab<span><span>, followed by second-line nivolumab<span>, and then two lines of conventional chemotherapy with paclitaxel and </span></span>cetuximab<span> followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12</span></span></span></span></span> <!-->months’ response, ongoing at the time of writing, and 42.5<!--> <!-->months’ survival since initiation of exclusive systemic management after failure of conventional treatment.</p></div><div><h3>Conclusion</h3><p>This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.</p></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"141 4","pages":"Pages 231-234"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report\",\"authors\":\"\",\"doi\":\"10.1016/j.anorl.2024.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Analysis of rechallenge with nivolumab<span> as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma<span> following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.</span></span></p></div><div><h3>Observation</h3><p><span><span>A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with </span>chemoradiotherapy<span> and surgery, was initially treated for recurrence with carboplatin<span>, 5-fluorouracile (FU) and cetuximab<span><span>, followed by second-line nivolumab<span>, and then two lines of conventional chemotherapy with paclitaxel and </span></span>cetuximab<span> followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12</span></span></span></span></span> <!-->months’ response, ongoing at the time of writing, and 42.5<!--> <!-->months’ survival since initiation of exclusive systemic management after failure of conventional treatment.</p></div><div><h3>Conclusion</h3><p>This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.</p></div>\",\"PeriodicalId\":48834,\"journal\":{\"name\":\"European Annals of Otorhinolaryngology-Head and Neck Diseases\",\"volume\":\"141 4\",\"pages\":\"Pages 231-234\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Annals of Otorhinolaryngology-Head and Neck Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879729624000206\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Annals of Otorhinolaryngology-Head and Neck Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879729624000206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report
Objective
Analysis of rechallenge with nivolumab as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.
Observation
A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with chemoradiotherapy and surgery, was initially treated for recurrence with carboplatin, 5-fluorouracile (FU) and cetuximab, followed by second-line nivolumab, and then two lines of conventional chemotherapy with paclitaxel and cetuximab followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12 months’ response, ongoing at the time of writing, and 42.5 months’ survival since initiation of exclusive systemic management after failure of conventional treatment.
Conclusion
This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.
期刊介绍：
European Annals of Oto-rhino-laryngology, Head and Neck diseases heir of one of the oldest otorhinolaryngology journals in Europe is the official organ of the French Society of Otorhinolaryngology (SFORL) and the the International Francophone Society of Otorhinolaryngology (SIFORL). Today six annual issues provide original peer reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches and review articles giving most up-to-date insights in all areas of otology, laryngology rhinology, head and neck surgery. The European Annals also publish the SFORL guidelines and recommendations.The journal is a unique two-armed publication: the European Annals (ANORL) is an English language well referenced online journal (e-only) whereas the Annales Françaises d’ORL (AFORL), mail-order paper and online edition in French language are aimed at the French-speaking community. French language teams must submit their articles in French to the AFORL site.
Federating journal in its field, the European Annals has an Editorial board of experts with international reputation that allow to make an important contribution to communication on new research data and clinical practice by publishing high-quality articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
